23andMe cuts 40% of its workforce and discontinues therapeutics division
NEW YORK (AP) — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest restructuring efforts were announced by 23andMe on Monday.
23andMe cuts 40% of its workforce, discontinues all therapy programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO Anne Wojcicki. The company said it is evaluating strategic ...
23andMe cuts 40% of its workforce
Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to "streamline operations and reduce costs."
23andMe to cut 40% of workforce, end therapeutics program
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the company announced Monday.
23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline
Me is further streamlining its operations as it discontinues its pipeline of cancer-related therapeutic programs while it evaluates alternatives for its clinical and preclinical assets.The South San Francisco,
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe customer? Here's what to know about the privacy of your genetic data.
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
Hosted on MSN1d
After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...
23andMe’s stock falls after company says there’s substantial doubt it can stay in business
Me Holding Co.’s stock turned down early Tuesday, after the DNA-testing company reported its latest quarterly loss, shedding ...
23andMe is ending its cancer research program and slashing over 200 jobs
Though 23andMe says the restructuring plan will cost it around $12 million, it expects to save more than $35 million as a ...
Yahoo Finance11h
23andMe to lay off more than 200 employees amid business struggles
The firm expects to save more than $35 million in annualized costs through the restructuring. CEO Anne Wojcicki told ...
The Business Journals1mon
23andMe's Anne Wojcicki now says her take-private plan is the best option for company
Anne Wojcicki ... private is its "the best path forward." Wojcicki, who this spring said she wanted to take 23andMe Holding Co. (Nasdaq: ME) private and wouldn't consider a third-party officer ...
Hosted on MSN6mon
23andMe Co-Founder Anne Wojcicki Is Considering Taking the Company Private
Wojcicki's buzzy health-tech startup saw its stock value drop to below $1 in recent months. Anne Wojcicki wants to take 23andMe private. On Wednesday, Wojcicki, CEO and co-founder of the San ...